Selective Histone Deacetylase Inhibitors with Anticancer Activity

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylase inhibitors (HDACIs) demonstrate efficacy in cancer treatment by modulating histone deacetylase activity and chromatin structure.
• Several HDACIs, including SAHA, FK228, belinostat, and panobinostat, are FDA-approved and show activity in both hematological and solid tumors.

Purpose of the Study:

• To review the advancements in the development of selective HDAC inhibitors.
• To highlight progress in both class-selective and isoform-selective HDAC inhibitors.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of research trends in selective HDAC inhibitor development.

Main Results:

• Significant progress has been made in designing HDACIs with improved selectivity.
• Selective HDAC inhibitors offer potential for targeted cancer therapy with reduced side effects.

Conclusions:

• The development of selective HDAC inhibitors is a key area of focus in cancer drug discovery.
• Further research into class- and isoform-selective HDACIs holds promise for next-generation cancer treatments.